Niraparib (Zejula) maintenance did not improve overall survival (OS) in patients with platinum-sensitive recurrent ovarian cancer in research presented at the Society of Gynecologic Oncology (SGO) ...
Approval reinforces Myriad’s leadership in comprehensive HRD testing and establishes MyChoice CDx as the only FDA-approved ...
Niraparib continued to show a benefit over placebo for patients with ovarian cancer regardless of HRD or gBRCA status. In the cohort of patients with non- gBRCA mutations who were either HRD-positive ...
Please provide your email address to receive an email when new articles are posted on . Women with advanced ovarian cancer derived significant quality-adjusted PFS benefit from niraparib compared with ...
Niraparib and abiraterone acetate regimen demonstrates clinically meaningful delay in disease progression, nearly halving the ...
For women with platinum-sensitive recurrent ovarian cancer, maintenance therapy using an individualized starting dose of niraparib (Zejula) did not improve overall survival (OS) despite producing a ...
Individualized starting dose (ISD) of niraparib reduces severe hematologic adverse events (AEs) compared to fixed starting dose in ovarian cancer patients. Implementing ISD lowers hematologic AE ...
The filing comes as recent upgrades to NCCN guidelines expand the role of testing in the treatment of ovarian cancer. Myriad Genetics this week submitted the first part of its application to the FDA ...
Ideaya Biosciences Inc. has announced FDA clearance of an IND for a GSK-sponsored phase I/II trial of GSK-101 (IDE-705), a small-molecule inhibitor of Polϴ helicase, in combination with GSK's PARP ...
Please provide your email address to receive an email when new articles are posted on . SAN FRANCISCO — The addition of niraparib to abiraterone acetate and prednisone improved outcomes for certain ...
Adding PARP inhibitor niraparib to standard prostate cancer treatment delayed disease progression in men with certain DNA repair gene mutations. The corresponding study was published in Nature ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results